Financing

Antibody drug conjugate
#Antibody drug conjugate (ADC) #Callio Therapeutics #Financing #Oncology #Start-ups

$187m supports a new generation of ADC therapies

Biotechnology company Callio Therapeutics has announced its launch with the closing of a $187 million Series A financing round.   Callio is focused on realising the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy.  The newly formed company, with headquarters in Seattle and Singapore,… Read More

#Business & Investment #Cancer Research #News #Start-up Zone

#Eikon Therapeutics #Financing #Melanoma #Oncology

Eikon secures $350.7 million to advance oncology programmes

Eikon Therapeutics has announced the initial closing of a $350.7 million Series D financing, led by existing investors. Since its founding in 2019, the company has privately raised over $1.1 billion.  “Eikon has made remarkable progress in advancing a pivotal-stage clinical pipeline and early-stage development programme… Read More

#Business & Investment #News

Scotland flag
#Bioprocessing #Biotechnology #Cell line development #Financing #uFraction8

Scottish biotech company secures £3.4m investment

uFraction8 has secured £3.4 ($4.2) million in new investment following the completion of a funding round led by Foresight Group.  Based in Falkirk with a fully-owned subsidiary in Poland, uFraction8’s microfiltration technology is designed to optimise cell and biomass production, offering a sustainable, energy-efficient alternative to traditional… Read More

#Business & Investment #News

#Financing #Helicore Biopharma #Monoclonal antibodies #Obesity #Weight loss

Obesity drug developer emerges from stealth with a $65m financing

Helicore Biopharma has announced its emergence from stealth mode with $65 million in Series A financing, co-led by founding investor Versant Ventures and by OrbiMed.  The company is focused on the discovery and development of first-in-class glucose-dependent insulinotropic peptide (GIP) antagonists for obesity and related conditions. … Read More

#Business & Investment #News

Map of Iceland
#Alzheimer's #Arctic Therapeutics #Dementia #Dermatology #Financing #Neuroscience

Scale-up explores anti-amyloid treatments for dementia

Icelandic drug discovery and development company Arctic Therapeutics (ATx) has announced the successful closing of a €26.5 million oversubscribed Series A financing from a syndicate of international investors.  The syndicate includes the EIC Fund, Iceland’s largest privately-held investment firm Kaldbakur, Investcorp-backed Sanos Group, Swiss-based Cerebrum DAO, The… Read More

#Business & Investment #News

#Epigenomics #Financing #Fundraising #Tune Therapeutics

Tune raises $175m to support epigenome editing programmes

Epigenome editing company Tune Therapeutics has announced the completion of over $175 million in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and Hevolution Foundation.  Tune Co-Founder Dr Charles Gersbach, whose research at Duke University formed the basis for Tune’s TEMPO epi-editing platform, commented: “Tune has… Read More

#Business & Investment #News

Business financing
#Asthma #Financing #Immunology #Monoclonal antibodies #Windward Bio

Windward Bio launches with $200 million

Windward Bio, a clinical-stage, drug development company focused on advanced immunological diseases, has announced its official launch.   OrbiMed, Novo Holdings, and Blue Owl Healthcare Opportunities lead the Series A financing of $200 million, with the co-investment of SR One, Omega Funds, RTW Investments, Qiming Venture Partners, Quan… Read More

#Business & Investment #News #Start-up Zone

#Business #Financing #Fundraising #Investment

New DDW Highlights podcast: 13 January 2025

The latest episode of the DDW Highlights podcast is now available to listen to and watch below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Our news round-up at the end of last year focused on drug… Read More

#News

#Business #Financing #Fundraising #Investment

This week in drug discovery (6-10 January) 

News round-up for 6-10 January by DDW Senior Digital Content Editor Diana Spencer. Our news round-up at the end of last year focused on drug discovery investment, so it is positive to see that this has also started strong in 2025, with a number of new acquisitions, research… Read More

#News

Bioprinting
#Aspect Biosystems #Bioprinting #Financing

$115 million supports development of bioprinted cell therapies

Bioprinted tissue therapeutics company Aspect Biosystems has closed a $115 million Series B financing round.   The financing was led by Dimension, and included Novo Nordisk, Radical Ventures, an undisclosed leading global investment firm, InBC, Pallasite Ventures, Pangaea Ventures, Rhino Ventures, and T1D Fund: A Breakthrough T1D Venture. Read More

#Business & Investment #News

#Business #Financing #Fundraising #Investment

Listen now: Last DDW Highlights episode of 2024

The latest episode of the DDW Highlights podcast is now available to listen to and watch below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. As we approach the end of 2024, it’s great to see that… Read More

#News

#Business #Financing #Fundraising #Investment

This week in drug discovery (16-20 December) 

News round-up for 16-20 December by DDW Senior Digital Content Editor Diana Spencer. As we approach the end of 2024, it’s great to see that investment in drug discovery is still going strong, with an impressive $300 million raised by AI-focused company SandboxAQ and another significant financing by… Read More

#News

#Artificial intelligence (AI) #Financing #Large language model (LLM) #SandboxAQ

AI drug discovery company announces $300m funding

SandboxAQ today announced a round of more than $300 million, which valued the company at $5.3 billion on a pre-money basis. The money came from investors Fred Alger Management, T Rowe Price Associates, Mumtalakat, Parkway Venture Capital, Breyer Capital, Rizvi Traverse, S32, US Innovative Technology Fund,… Read More

#Business & Investment #News #Trending News

Person using a calculator
#Autoimmune disease #Financing #Immunomodulators #Nuvig Therapeutics #Phase II trial

Immunomodulatory therapeutics company raises $161m

Nuvig Therapeutics has closed a $161 million Series B financing and announced plans to progress to Phase II development with its immunomodulator for inflammatory autoimmune diseases.  The financing was co-led by Sanofi Ventures, Blue Owl Healthcare Opportunities (formerly Cowen Healthcare Investments), and Norwest Venture Partners. … Read More

#Business & Investment #News

Woman standing on scales
#Antag Therapeutics #Financing #Obesity #Weight loss

€80 million financing will advance GIPR drugs for obesity

Biopharmaceutical company Antag Therapeutics has announced the closing of an €80 million Series A financing.   The round was led by Versant Ventures, with participation from Novo Holdings, SR One, Dawn Biopharma (a platform controlled by KKR), Pictet, Longview Ventures (an affiliate of Broadview Ventures), and Export and… Read More

#Business & Investment #News